Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

The pathogenic role of epithelial and endothelial cells in early-phase COVID-19 pneumonia: victims and partners in crime



Current understanding of the complex pathogenesis of COVID-19 interstitial pneumonia pathogenesis in the light of biopsies carried out in early/moderate phase and histology data obtained at postmortem analysis is discussed. In autopsies the most observed pattern is diffuse alveolar damage with alveolar-epithelial type-II cell hyperplasia, hyaline membranes, and frequent thromboembolic disease. However, these observations cannot explain some clinical, radiological and physiopathological features observed in SARS-CoV-2 interstitial pneumonia, including the occurrence of vascular enlargement on CT and preserved lung compliance in subjects even presenting with or developing respiratory failure. Histological investigation on early-phase pneumonia on perioperative samples and lung biopsies revealed peculiar morphological and morpho-phenotypical changes including hyper-expression of phosphorylated STAT3 and immune checkpoint molecules (PD-L1 and IDO) in alveolar-epithelial and endothelial cells. These features might explain in part these discrepancies.


Coronavirus disease 2019 (COVID-19) is a pandemic disease characterized by clinical variability, with patients developing mild symptoms and others experiencing an interstitial pneumonia that can rapidly progress, in a minority of cases, to severe life threatening respiratory failure requiring mechanical ventilation or even extra corporeal membrane oxygenation ECMO [1]. The worldwide spread of infection and the lack of reliable and accepted therapies to prevent and cure the severe form and its possible consequences urge for a clear understanding of the pathogenic mechanisms and an explanation for the observed clinical variability. Although it is now widely accepted that infection can trigger a hyper-inflammatory response (also termed “cytokine storm”) [2], the pathogenic role of different cell types and the mechanisms leading to different disease phases and endotypes are not fully understood [3]. The heterogeneity of clinical presentations is likely conditioned by the viral burden, the efficacy of innate and adaptive immune responses, genetic predisposition, and the occurrence and severity of preexisting comorbidities (such as older age, obesity, hypertension, and diabetes mellitus) [4, 5]. From the beginning of COVID-19 pandemic, when soon the need of pathological data became evident, a large number of postmortem studies have been performed worldwide, providing relevant information mainly regarding the pathogenic mechanisms occurring in severe cases (extended lists of references are available in previous reviews) [3, 6,7,8,9,10].

Postmortem studies

All reports indicate the lungs as the principal target of SARS-CoV-2 in deceased cases [3, 6,7,8,9,10,11,12,13,14]. The most frequent pathological pattern observed in autoptic lung is “diffuse alveolar damage” (DAD), with hyaline membranes, alveolar fibrinous edema and type-II alveolar-epithelial cell (AECII) hyperplasia. Most cases present features typical of the exudative phase, whereas the proliferative findings including interstitial fibrosis are common in subjects with a long lasting clinical history. Such aspects occur in acute respiratory distress syndrome (ARDS) regardless of the cause, including H1N1 pneumonia, SARS, and MERS, so that the “peculiarity” of the pathogenic mechanisms triggered by the SARS-CoV-2 has been challenged [15, 16]. In postmortem reports the time lapse from symptoms onset to tissue sampling was highly variable, and pulmonary superinfections were also documented in a significant number of cases. Inflammatory cell accrual was generally described as heterogeneous, with macrophage accumulation in most cases, variable lymphocyte infiltration (sometimes perivascular) and occasional widespread infiltration of granulocytes mainly when a superimposed bacterial infection was documented. In many studies the occurrence of thrombotic events was reported, varying from small capillary clots to thrombosis in the larger vessels [17,18,19,20]. These latter findings have been linked up to the higher frequency of coagulation abnormalities observed in COVID-19, compared to those with non-COVID-19 ARDS, and were considered clinically relevant, advocating the need for anticoagulation therapeutics [21, 22]. Infiltration of vascular wall by inflammatory cells with necrosis (vasculitis) was also rarely reported.

The general view that the DAD pattern can be sufficient to explain the pathogenesis of COVID-19 progression may be disputed for several reasons. First, the possible pathogenic contribution of confounding factors, including the use of oxygen at high doses and the impact of barotrauma due to the positive pressure mechanical ventilation should be considered. The complications following intubation, such as secondary ventilator-induced lung injury are well known and could be the cause of some DAD features reported at autopsy [23]. The impact of pulmonary thromboembolism or in situ thrombosis and superimposed inflammation due to bacterial and/or fungal infections should be also taken into account. Secondly, in a minority of reports different patterns are described, including organizing pneumonia, acute fibrinous organizing pneumonia and lymphocytic viral pneumonia [24, 25]; this heterogeneity may suggest to avoid a simplistic histological lumping [26]. Significant heterogeneity has also been revealed in COVID-19 by immunological, radiological, and clinical studies, accounting for the evidence of different disease phenotypes [27,28,29]. In fact, a number of studies have revealed that COVID-19 may present with features that are not typical for ARDS, including a preserved compliance, hyper-perfusion of affected pulmonary areas, loss of hypoxic vasoconstriction, and “silent hypoxia” (or “happy hypoxia”), i.e., a state of low oxygen saturation without subjective perception of respiratory distress [29,30,31,32,33,34,35,36]. Several explanations have been advanced for these unusual findings, including neurological causes, subtle clotting, perfusion abnormalities, organizing pneumonia, but no reliable evidence has been provided so far [36,37,38,39,40]. Thus this “hot” topic remains matter of ongoing debate because of its high clinical relevance [29, 30, 39,40,41,42,43,44]. We hypothesize that histological information regarding the “early” phases of the disease, when a mild to moderate pneumonia is diagnosed in a swab-positive patient, could be crucial to clarify the above described issues, and also in suggesting the best therapy for minimizing disease progression [45].

Perioperative samples

Only a few reports of early/moderate COVID-19 pneumonia are currently available, collected during surgical procedures carried out in patients in which the infection by SARS-CoV-2 was eventually documented (Table 1) [46,47,48,49,50]. In all these studies a pattern of lung injury not corresponding to the typical DAD pattern was reported, with AECII hyperplasia, but without hyaline membranes. Other features included scanty fibrosis, interstitial inflammation, intra-alveolar edema and/or proteinaceous exudates in variable quantity. Abnormal perivascular accumulation of CD4+ helper T-lymphocytes and CD163+ macrophages was described in a single case [49]. Although sparse, these reports can provide relevant information regarding the “missing link” in disease progression, and have raised interest and discussion for their contribute in understanding the early mechanisms of lung injury following SARS-CoV-2 infection [6, 26, 51, 52].

Table 1 Available histological studies of early-phase COVID-19 pneumonia (perioperative samples and biopsies).

Live diagnostic biopsies

A more systematic description of early/moderate COVID-19 interstitial pneumonia was recently reported by our group, analyzing a series of 12 cases (Table 1) [53]. The patients in this series, recognized by nasal swab and/or bronchoalveolar lavage PCR test as harboring SARS-CoV-2 infection, underwent lung cryobiopsy in the course of the disease (<20 days from symptoms’ onset). All patients had a CT scan documenting typical lung opacities and a variable degree of hypoxemia, but with no needs of intubation and mechanical ventilation. As observed in the perioperative case reports, signs of acute lung injury were present, but without the typical features of the DAD pattern. Edema and cellular debris occurred only occasionally in alveolar spaces, and hyaline membranes were absent in all 12 cases. Interstitial fibrosis was either focal or minimal. AECII hyperplasia was heterogeneous and characterized by an unusual “patchy” distribution, with epithelial clusters ranging from isolated small aggregates to wide proliferation of micronodular and/or pseudo-papillary sprouts of AECII, interposed to variable proportions of normally looking type-I pneumocytes (Fig. 1a, b).

Fig. 1: Early-phase COVID-19 pneumonia.

Cytokeratin-7 (CK7) immunostaining provides a better evaluation of the peculiar pattern showing patchy AECII hyperplasia and increased number of enlarged vascular structures with perivascular lymphoid infiltrate (a, b). No hyaline membranes are evidenced. Diffuse nuclear expression of Tyr705 pSTAT3 immunostaining in activated AECII and blood vessels (c). Diffuse PD-L1 expression in blood vessels and intraluminal macrophage aggregates (d). Diffuse IDO expression in endothelial cells in both interstitial capillaries and post-capillary venules (e).

The target of SARS-CoV-2 infection

FISH analysis in this series revealed SARS-CoV-2 RNA in a proportion (<10%) of AECII, without any positivity in alveolar macrophages and blood vessels. This finding is consistent with the notion that epithelial cells are the principal target of SARS-CoV-2 infection in both the upper respiratory system and the distal lung [54,55,56]. AECII steadily express the two key host proteins utilized by the virus to gain entry and replicate within cells: angiotensin-converting enzyme 2 (ACE2) and the cell surface transmembrane protease serine 2 (TMPRSS2) [57]. SARS-CoV-2 infected cells can be detected in tissues by several methods characterized by variable levels of sensitivity and specificity, including molecular in situ analysis, immunohistochemistry, and electron microscopy [58,59,60]. SARS-CoV-2 infected alveolar-epithelial cells have been consistently detected in most reports using these methods, whereas the infection evidence for other cell types, including endothelial cells and macrophages, is scarce and contradictory [17, 60,61,62], thus suggesting that infection of cells other than epithelial ones occurs rarely in early-phase COVID-19 pneumonia, and does not represent a major pathogenic mechanism.

AECII in early-phase pneumonia exhibit a high proliferation rate (>50% positive cells) at Ki67-immunostaining, as also observed in DAD [63]. The lack of necrosis or apoptosis (as defined by cleaved caspase-3 analysis) suggests that SARS-CoV-2 infection does not induce widespread epithelial cell death (either mediated by the virus or by cytotoxic cells), at least in early-phase cases, thus explaining the lack of hyaline membranes. Although the evidence that AECII are a target of SARS-CoV-2 infection is generally accepted, little attention has been provided to the fate of these cells after infection, as well as the potential effects on the renewal mechanisms of gas-exchange units. In most acute pulmonary diseases the main targets of damage are either the easily injured type-I pneumocytes, endothelial cells, or both [64]. The eventually occurring AECII hyperplasia is regarded as a reparative mechanism aimed at replacing the sloughed type-I pneumocytes, which allows a correct balance between epithelial and mesenchymal growth and regulated by a complex array of developmental-related signaling pathways within specialized niches [65]. The lack of hyaline membranes in early-phase pneumonia may suggest that damage of type-I cells does not represent a major event, thus explaining the relative preservation of alveolar structure and gas-exchange functions. In addition, accumulation of collagen and myofibroblasts in interstitial spaces is minimal in early-phase COVID-19, and the sensitive marker of ongoing fibrosis tubulin-beta-3 is either absent or minimal, at variance with typical DAD where strong and diffuse tubulin-beta-3 is expressed by interstitial myofibroblasts [66]. These findings provide relevant histological support to the clinical evidence that COVID-19 acute pneumonia is different from ARDS, as previously discussed.

AECII express factors involved in activation of the “cytokine storm”

Hyperplastic AECII in COVID-19 early-phase pneumonia diffusely express the Tyr705 phosphorylated form of STAT3 (pSTAT3) [53], a master gene product involved in the JAK2/STAT3 pathway and cytokine abnormal production in COVID-19 [67] (Fig. 1c). Similar findings were described in a single postmortem early-phase case by Brown et al. [68]. Interestingly, IL-6 RNA expression was also evidenced by an in situ analysis of cells corresponding for morphology and distribution to SARS-CoV-2 infected AECII [53]. AECII are physiologically committed to produce IL-6 when stimulated by cytokines, and the STAT3 pathway is involved in pneumocyte differentiation [69]. Taken together these findings suggest that after viral infection of pneumocytes a local overproduction of cytokines is triggered within the pulmonary microenvironment, without necessarily increasing their systemic level as observed in severe COVID-19 [70]. The occurrence of an infection-related shift from STAT1 to STAT3-pathway activation has been recently proposed as central in COVID-19, triggering a cascade of pathogenic events that can explain many features of the disease [71]. In addition, IL-6 is able to activate the STAT3 and NF-kB pathways also in nonimmune cells, including epithelial cells and endothelial cells, triggering a positive feedback loop of NF-κB activation [67, 72, 73]. Amplification of this pro-inflammatory process is likely provided in disease progression by involvement of other cell types (e.g., macrophages), which increase the production and diversification of cytokines leading to an overt DAD. This finding may be relevant to understand the time frame for the proper use of molecules modulating the JAK2/STAT3 pathway [74, 75].

Vascular involvement in COVID-19 pneumonia

There is widespread consensus on considering vascular damage as a central player in the cascade of coagulation abnormalities eventually leading to thromboembolic complications in severely ill COVID-19 patients [76,77,78,79]. Vascular dysfunction is associated with vasoconstriction, inflammation, permeability and coagulation abnormalities, and is common in several comorbidities with ominous prognosis in COVID-19, including obesity, older age, diabetes mellitus, hypertension, chronic lung disease, coronary artery disease and heart failure [4, 80, 81]. The infection could decrease the availability of ACE2, thus impairing its counteracting functions on the renin-angiotensin system with eventual alteration of blood pressure and electrolyte homeostasis [82, 83].

Different mechanisms can be hypothesized for the derangement of vascular homeostasis, including different types of SARS-CoV-2 interactions with endothelial receptors. Some evidence for a direct endothelial infection by SARS-CoV-2 has been provided in pulmonary and extrapulmonary sites using electron microscopic images [18, 61], a methodological approach that has been questioned [84,85,86]. In addition, endothelial infected cells were not reported in postmortem and antemortem studies, where sensitive immunohistochemical and molecular in situ methods were applied [60]. Furthermore, endothelial cells express high amounts of the virus–receptor ACE2, but not TMPRSS2 necessary for spike protein priming [87]. Additional factors involved in endothelial damage and activation include angiotensin-II [88], a factor whose level in the plasma sample from COVID-19 infected patients is elevated and linearly correlated with viral load and lung injury [89]. IL-6 also promotes a sustained loss of endothelial barrier function via JAK-STAT3 [90], and this activity may be particularly effective within the restricted alveolar microenvironment. Indeed, experimental endotheliopathy can be triggered by plasma from severely ill patients [91]. An interesting alternative is provided by the interaction of viral spike proteins with endothelial receptors. In a recent experimental study Suzuki et al. could demonstrate that SARS-CoV-2 spike protein alone, without the rest of the viral components, is able to elicit cell signaling in human host cells [92]. Pathogenic interaction of spike protein with the transmembrane pattern recognition receptor TLR4 (Toll like receptor-4) has been hypothesized in COVID-19 [93]. Along this line, activation of the endothelial TLR4/NF-kB pathway has a critical role in glucose-induced inflammation and damage in diabetes, a condition predisposing to severe complication in COVID-19 [1, 94]. Whatever the triggering cause of endothelial damage, the eventual vascular dysfunction is considered a relevant pathogenic component in the disease severity [95]. The occurrence of vascular damage in COVID-19 is confirmed by the increase of various biomarkers of endothelial damage including circulating endothelial cells and endothelial extracellular vesicles [96, 97].

Endothelial cells express factors involved in the cytokine storm, immune checkpoint and vasodilation

Histological evaluation of early-phase COVID-19 on cryobiopsies [53] revealed relevant abnormalities in pulmonary vessels, which increased in number, showing congestion, dilation and tortuosity (Fig. 1a). According to this report, the thickened edematous walls of post-capillary venules are often infiltrated by CD4+ T-lymphocytes, without overt vasculitis or endothelialitis (Fig. 1a) [53]. A striking finding was the strong and diffuse expression of pSTAT3 in endothelial cells, together with diffuse expression of immune checkpoint molecule Programmed Death-Ligand 1 (PD-L1) and indoleamine 2,3-dioxygenase 1 (IDO) (Fig. 1c–e). These unexpected findings raise a number of considerations that might contribute to a better understanding of COVID-19 pneumonia.

The observed hyper-expression of pSTAT3-Tyr705) not only in AECII but also in endothelial cells in COVID-19 early-phase reinforces the above reported hypothesis of a local, peculiar triggering of this potent pro-inflammatory pathway in the pulmonary microenvironment. Interestingly, the specific phosphor-Tyr705 of STAT3 has been experimentally associated to inflammation and coagulopathy in experimental sepsis [98], as also commonly observed in COVID-19 [18, 37, 78, 99].

Programmed death-ligand 1 (PD-L1)

The robust expression in endothelial cells of PD-L1 and IDO in early-phase/moderate COVID-19 pneumonia (minimal or even absent in normal lung), may explain in part the severe defects in innate and adaptive immunity observed in COVID-19, as also observed in H9N2 avian influenza virus infection [100]. Experimental evidence has been provided that PD-L1 expression is induced in endothelial cells by interferons and IL-12 [101]. In cancer, the endothelial cells can participate in immune inhibition by immune cell checkpoint signaling, since PD-L1 is highly expressed on endothelial cells and concurs in limiting the infiltration by CD8+ T cells [102, 103]; similar mechanisms are likely occurring in COVID-19. Interestingly, the inhibitory signals exerted by pulmonary endothelial PD-L1 are involved in sepsis and acute lung damage, and are exploited as potential target for therapy of these diseases [104,105,106].

Further inhibitory signals can be delivered within the alveolar microenvironment by the many monocytes/macrophages expressing PD-L1 which can be demonstrated in early-phase/moderate pneumonia forming endoluminal clusters (Fig. 1d). The nature and role of these macrophages within the alveoli is not clear, since they express an unusual “hybrid” phenotype including dendritic-cell markers such as CD123 and CD205. Lack of expression of CD117 and CD303 excluded other cell types characterized by constitutive expression of CD123/IL3AR (i.e., mast cells and plasmacytoid dendritic cells). Interestingly, a similar phenotype is induced in monocytes by pulmonary epithelial cells that promote TH17 differentiation [107]. The putative inhibitory role of these intra-alveolar macrophages on adaptive immune response following infection was already suggested and related to their expression of immunoregulatory molecules [108, 109]. The role of monocytes and macrophages in the pathogenesis of COVID-19 has been extensively analyzed [110, 111], but the specific significance of PD-L1+, CD123+ alveolar macrophages during early-phase pneumonia is far from clear and warrants further investigation.

Indoleamine 2,3-dioxygenase 1 (IDO)

IDO is an intracellular monomeric, heme-containing enzyme, coded by the gene IDO-1, which controls the L-tryptophan breakdown to N-formylkynurenine, thus regulating the availability and metabolic activity of this essential amino acid [112]. Tryptophan catabolites have an antimicrobial role, but can also highjack the host immune response in chronic viral infection since they can suppress T-cell responses and promote tolerance [113, 114]. In normal tissues IDO is expressed by dendritic cells in lymphoid organs, and its immune-inhibitory activity is considered of paramount importance for their function [115, 116]. In COVID-19 T-cell lymphopenia and CD8-cell exhaustion are very common findings, and IDO-related tryptophan depletion might be involved in establishing these immune dysfunctions [117, 118].

The endothelial expression of IDO is heterogeneous in different tissues: in human placenta strong IDO activity and expression have been demonstrated and likely exerts a fundamental role in feto-maternal tolerance and vascular tone regulation; IDO insufficiency is involved in intrauterine growth restriction and pre-eclampsia [119]. In the lung, experimental IDO deficiency impairs vascular development, and is able to increase IL-6 during tumor formation [120]. The IDO-mediated mechanisms implicated in vascular tone regulation include the production of kynurenin, a tryptophan catabolite with vascular relaxing activity [121, 122], and also its nitrite reductase activity, likely involved in observed local production of nitric oxide (NO) under anaerobic conditions, as recently demonstrated [123]. The abnormally increased activity of IDO demonstrated by Doglioni et al. [53] is likely responsible for the pulmonary vasodilation and vasoplegia characterizing early-phase/moderate COVID-19 pneumonia, as previously described. This finding is hard to be reconciled with the occurrence of vascular dysfunction, a condition considered a relevant pathogenic mechanism in severe COVID-19 cases. Vascular dysfunction is characterized by reduced vascular relaxation, vasoconstriction, reduced NO synthesis, and increase in angiotensin-II related inflammation and hypertension [122, 124], at variance with the observed increase of vascular enlargement and vasoplegia in early-phase COVID-19 pneumonia, as discussed above [125, 126]. Nevertheless, this complex scenario may be explained by the proposed biphasic presentation of COVID-19. The early type-L pattern (also defined as CARDS—coronavirus disease-associated acute respiratory distress syndrome) is characterized by preserved compliance, hypoxemia and out of proportion hypocapnia [29, 127]. In some patients orthodeoxya and platypnea similarly to that observed in well known causes of right to left shunt (patent foramen ovale, hepatopulmonary syndrome) is even clearly documented [128, 129]. These physiopathologic aspects are related to the increased vascular bed (mainly for vascular relaxation) around not-collapsed alveoli [126].

The severe type-H pattern observed in either progressed cases or in a few early cases, on the other hand, is likely characterized by bona fide vascular dysfunction, extended alveolar damage leading to alveolar collapse. Vascular relaxation and mechanisms underlying its development, in particular IDO activity, warrant further investigation, since may be a key factor in determining either the positive or negative evolution of the disease. Indeed, IDO can determine perfusion defects and hypoxia, and activation of the IDO-kynurenine pathway characterizes experimental sepsis-related hypotension, a dramatic state that can be reversed by IDO inhibition [121]. On the other hand, the IDO-kyruneine pathway exerts a protective role against development of pulmonary hypertension and lung damage in experimental studies [130, 131], and this complexity should be carefully taken into account when planning potential therapeutic strategies.

Experimental evidence has been provided for an IDO-dependent suppression of type-I IFNs production in viral infection, and this activity may contribute to the overall pathogenic type-1 IFN deficiency observed in COVID-19 [132]. Evidence for impaired availability of type-1 IFN in COVID-19 is robust and may be supported through different mechanisms [133,134,135,136]. Clinical complications observed in COVID-19 may be explained, at least in part, by IDO hyper-expression. For instance, increased IDO-mediated degradation of L-tryptophan has been demonstrated in morbid obesity, a predisposing condition to severe complications in COVID-19 [137, 138].

In most normal tissues endothelial IDO expression is negligible, but it increases after non canonical NF-kB-dependent IFN-γ stimulation and in cancer, where it is involved in tumor resistance to immune response and immunotherapy [112, 139,140,141]. IL-6 and the STAT3 pathway are also regulators of IDO expression [71, 141], and vascular co-expression of pSTAT3 and IDO in the lung further supports their causative role in COVID-19 pathogenesis. The similarities observed in IDO-related mechanisms in COVID-19 pneumonia and cancer are intriguing, and the evaluation of clinical effects of checkpoint inhibitor therapies in SARS-CoV-2 infected cancer patients may provide future useful information regarding their possible beneficial or detrimental effects on COVID-19 pneumonia [142, 143].

Concluding remarks

All these data taken together confirm the central role of infected AECII in COVID-19. The progressive proliferation of pSTAT3 expressing AECII is nevertheless accompanied by diffuse morphologic and phenotypic abnormalities of the parenchymal blood vessels (dilatation, hyper-expression of pSTAT3, and its targets PD-L1, and IDO), without evidence of endothelial infection. These findings strongly suggest that in COVID-19 a pathogenic cross-talk between epithelial infected cells and endothelial noninfected cells takes place, in agreement with experimental co-culture data [144]. The demonstration of early activation of the STAT3 pathway and its target genes within the alveolar microenvironment may explain a variety of pathogenic features of COVID-19, as previously hypothesized) [71]: 1. the overproduction of plasminogen activator inhibitor-1 (PAI-1) may be involved in the observed derangement of coagulation mechanisms, 2. the robust immune-inhibitory signals exerted by PDL-1 and IDO may contribute to the impairment of cellular immune response, and 3. the physiopathological abnormalities with silent hypoxia related to vasoplegia as previously discussed. Another point to consider is the accumulation in the alveolar spaces of macrophages with an “inflammatory” phenotype; their role is not yet clear possibly representing an attempt to limit the alveolar damage or, viceversa, the trigger that multiply the damage.

The histological features characterizing early-phase/moderate pneumonia finally provide the anatomic ground to interpret the COVID-19 associated CT features, including ground-glass opacities and the “vascular enlargement pattern”, a still debated finding with relevant diagnostic potential [126, 145]. The nature of these gravity dependent imaging changes are matter of speculation, but according to available findings they can be reliably ascribed to vascular enlargement, blood stasis and macrophage accumulation, all features that may help in defining diagnostic and prognostic information. Interestingly, imaging abnormalities are also frequent in asymptomatic SARS-CoV-2 infected cases [146, 147], thus suggesting that vasoplegia can occur very early in the disease.

In conclusion, although AECII represent the prevalent target of viral infection and the first trigger of localized IL-6 production and STAT3-pathway activation within the alveolar microenvironment, endothelial cells appear crucial in providing the pulmonary pathophysiological ground to the disease, as shown in the pathogenic scheme here proposed (Fig. 2). This is why, in COVID-19, these two cell components behave as “victims and partners in crime”. This hypothetical pathogenic scheme needs to be validated on larger cohorts, investigating and comparing the morphological and molecular features of the different cell components as observed in early-phase pneumonia with postmortem samples, with the aim to unveil the mechanisms determining the heterogeneity and evolution risks and thus paving the way to personalized therapies in different disease phenotypes [148]. The possible spreading of infection to macrophages within the alveolar microenvironment is a likely candidate for explaining the systemic involvement of cytokine storm and dramatic evolution of disease severity in predisposed patients [149, 150].

Fig. 2: Hypothetical mechanisms involved in early-phase COVID-19 pneumonia, as discussed in this review.

The principal steps include 1. Viral infection of AECII, 2. activation of the STAT3 pathway in AECII, 3. Abnormal STAT3-mediated cross-talk between infected AECII and noninfected endothelial cells, 4. increased expression of PD-L1 (endothelial cells and macrophages) inducing checkpoint immune inhibition of adaptive immune responses, 5. Endothelial hyper-expression of IDO inducing dilation and relaxation of pulmonary vessels, and 6. Diffusion–perfusion mismatch, shunting, pathophysiological changes, absence of alveolar collapse, vasoplegia, and “happy hypoxia”.


  1. 1.

    Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497–506.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  2. 2.

    Fajgenbaum DC, June CH. Cytokine storm. N Engl J Med. 2020;383:2255–573.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  3. 3.

    Polak SB, Van Gool IC, Cohen D, von der Thüsen JH, van Paassen J. A systematic review of pathological findings in COVID-19: a pathophysiological timeline and possible mechanisms of disease progression. Mod Pathol. 2020;33:2128–38.

    CAS  PubMed  Article  Google Scholar 

  4. 4.

    Zhou F, Yu T, Du R, Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395:1054–62.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  5. 5.

    Pairo-Castineira E, Clohisey S, Klaric L, Bretherick AD, Rawlik K, Pasko D, et al. Genetic mechanisms of critical illness in Covid-19. Nature. 2021;591:92–8.

    PubMed  Article  CAS  Google Scholar 

  6. 6.

    Nicholson AG, Osborn M, Devaraj A, Wells AU. COVID-19 related lung pathology: old patterns in new clothing? Histopathology. 2020;77:169–72.

    PubMed  PubMed Central  Article  Google Scholar 

  7. 7.

    Eketunde AO, Mellacheruvu SP, Oreoluwa P. A review of postmortem findings in patients with COVID-19. Cureus. 2020;12:e9438.

    PubMed  PubMed Central  Google Scholar 

  8. 8.

    Mohanty SK, Satapathy A, Naidu MM, Mukhopadhyay S, Sharma S, Barton LM, et al. Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and coronavirus disease 19 (COVID-19)—anatomic pathology perspective on current knowledge. Diagn Pathol. 2020;15:103.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  9. 9.

    Calabrese F, Pezzuto F, Fortarezza F, Hofman P, Kern I, Panizo A, et al. Pulmonary pathology and COVID-19: lessons from autopsy. The experience of European Pulmonary Pathologists. Virchows Arch. 2020;477:359–72.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  10. 10.

    Salerno M, Sessa F, Piscopo A, Montana A, Torrisi M, Patanè F, et al. No autopsies on COVID-19 deaths: a missed opportunity and the lockdown of science. J Clin Med. 2020;9:1472.

    CAS  PubMed Central  Article  PubMed  Google Scholar 

  11. 11.

    Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020;8:420–2.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  12. 12.

    Barton LM, Duval EJ, Stroberg E, Ghosh S, Mukhopadhyay S. COVID-19 Autopsies, Oklahoma, USA. Am J Clin Pathol. 2020;153:725–33.

    CAS  PubMed  Article  Google Scholar 

  13. 13.

    Bradley BT, Maioli H, Johnston R, Chaudhry I, Fink SL, Xu H, et al. Histopathology and ultrastructural findings of fatal COVID-19 infections in Washington State: a case series. Lancet. 2020;396:320–32.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  14. 14.

    Tian S, Xiong Y, Liu H, Niu L, Guo J, Liao M, et al. Pathological study of the 2019 novel coronavirus disease (COVID-19) through postmortem core biopsies. Mod Pathol. 2020;33:1007–14.

    CAS  PubMed  Article  Google Scholar 

  15. 15.

    Hariri LP, North CM, Shih AR, Israel RA, Maley JH, Villalba JA, et al. Lung histopathology in coronavirus disease 2019 as compared with severe acute respiratory sydrome and H1N1 influenza: a systematic review. Chest. 2021;159:73–84.

    CAS  PubMed  Article  Google Scholar 

  16. 16.

    Konopka KE, Nguyen T, Jentzen JM, Rayes O, Schmidt CJ, Wilson AM, et al. Diffuse alveolar damage (DAD) resulting from coronavirus disease 2019 Infection is morphologically indistinguishable from other causes of DAD. Histopathology. 2020;77:570–8.

    PubMed  Article  Google Scholar 

  17. 17.

    Carsana L, Sonzogni A, Nasr A, Rossi RS, Pellegrinelli A, Zerbi P, et al. Pulmonary post-mortem findings in a series of COVID-19 cases from northern Italy: a two-centre descriptive study. Lancet Infect Dis. 2020;20:1135–40.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  18. 18.

    Ackermann M, Verleden SE, Kuehnel M, Haverich A, Welte T, Laenger F, et al. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19. N Engl J Med. 2020;383:120–8.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  19. 19.

    Menter T, Haslbauer JD, Nienhold R, Savic S, Deigendesch H, Frank S, et al. Post-mortem examination of COVID19 patients reveals diffuse alveolar damage with severe capillary congestion and variegated findings of lungs and other organs suggesting vascular dysfunction. Histopathology. 2020;77:198–209.

    PubMed  PubMed Central  Article  Google Scholar 

  20. 20.

    Edler C, Schröder AS, Aepfelbacher M, Fitzek A, Heinemann A, Heinrich F, et al. Dying with SARS-CoV-2 infection-an autopsy study of the first consecutive 80 cases in Hamburg, Germany. Int J Leg Med. 2020;134:1275–84.

    Article  Google Scholar 

  21. 21.

    Helms J, Tacquard C, Severac F, Leonard-Lorant I, Ohana M, Delabranche X, et al. High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. Intensive Care Med. 2020;46:1089–98.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  22. 22.

    Connors JM, Levy JH. COVID-19 and its implications for thrombosis and anticoagulation. Blood. 2020;135:2033–40.

    CAS  Article  Google Scholar 

  23. 23.

    Nieman GF, Gatto LA, Habashi NM. Impact of mechanical ventilation on the pathophysiology of progressive acute lung injury. J Appl Physiol. 2015;119:1245–61.

    CAS  PubMed  Article  Google Scholar 

  24. 24.

    Copin MC, Parmentier E, Duburcq T, Poissy J, Mathieu D, Lille COVID-19 ICU and Anatomopathology Group. Time to consider histologic pattern of lung injury to treat critically ill patients with COVID-19 infection. Intensive Care Med. 2020;46:1124–6.

    CAS  PubMed  Article  Google Scholar 

  25. 25.

    Buja LM, Wolf DA, Zhao B, Akkanti B, McDonald M, Lelenwa L, et al. The emerging spectrum of cardiopulmonary pathology of the coronavirus disease 2019 (COVID-19): report of 3 autopsies from Houston, Texas, and review of autopsy findings from other United States cities. Cardiovasc Pathol. 2020;48:107233.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  26. 26.

    Epelbaum O, Galperin I. In defence of extrapolation but not improvisation in SARS-CoV-2 lung disease. Breathe (Sheff). 2020;16:200113.

    Article  Google Scholar 

  27. 27.

    Nienhold R, Ciani Y, Koelzer VH, Tzankov A, Haslbauer JD, Menter T, et al. Two distinct immunopathological profiles in autopsy lungs of COVID-19. Nat Commun. 2020;11:5086.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  28. 28.

    Simpson S, Kay FU, Abbara S, Bhalla S, Chung JH, Chung M, et al. Radiological Society of North America Expert Consensus Statement on reporting chest CT findings related to COVID-19. endorsed by the Society of Thoracic Radiology, the American College of Radiology, and RSNA—Secondary Publication. J Thorac Imaging. 2020;35:219–27.

    PubMed  Article  Google Scholar 

  29. 29.

    Gattinoni L, Chiumello D, Caironi P, Busana M, Romitti F, Brazzi L, et al. COVID-19 pneumonia: different respiratory treatments for different phenotypes? Intensive Care Med. 2020;46:1099–102.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  30. 30.

    Gattinoni L, Coppola S, Cressoni M, Busana M, Rossi S, Chiumello D. COVID-19 does not lead to a “typical” acute respiratory distress syndrome. Am J Respir Crit Care Med. 2020;201:1299–300.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  31. 31.

    Mahjoub Y, Rodenstein DO, Jounieaux V. Severe Covid-19 disease: rather AVDS than ARDS? Crit Care. 2020;24:327.

    PubMed  PubMed Central  Article  Google Scholar 

  32. 32.

    Maley JH, Winkler T, Hardin CC. Heterogeneity of acute respiratory distress syndrome in COVID-19: “Typical” or Not? Am J Respir Crit Care Med. 2020;202:618–9.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  33. 33.

    Busana M, Schiavone M, Lanfranchi A, Forleo GB, Ceriani E, Cogliati CB, et al. Non-invasive hemodynamic profile of early COVID-19 infection. Physiol Rep. 2020;8:e14628.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  34. 34.

    Dhont S, Derom E, Van Braeckel E, Depuydt P, Lambrecht BN. The pathophysiology of ‘happy’ hypoxemia in COVID-19. Respir Res. 2020;21:198.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  35. 35.

    Simonson TS, Baker TL, Banzett RB, Bishop T, Dempsey JA, Feldman JL, et al. Silent hypoxaemia in COVID-19 patients. J Physiol. 2021;599:1057–65.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  36. 36.

    Santamarina MG, Boisier D, Contreras R, Baque M, Volpacchio M, Beddings I. COVID-19: a hypothesis regarding the ventilation-perfusion mismatch. Crit Care. 2020;24:395.

    PubMed  PubMed Central  Article  Google Scholar 

  37. 37.

    Leisman DE, Deutschman CS, Legrand M. Facing COVID-19 in the ICU: vascular dysfunction, thrombosis, and dysregulated inflammation. Intensive Care Med. 2020;46:1105–8.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  38. 38.

    Nouri-Vaskeh M, Sharifi A, Khalili N, Zand R, Sharifi A. Dyspneic and non-dyspneic (silent) hypoxemia in COVID-19: Possible neurological mechanism. Clin Neurol Neurosurg. 2020;198:106217.

    PubMed  PubMed Central  Article  Google Scholar 

  39. 39.

    Herrmann J, Mori V, Bates JHT, Suki B. Modeling lung perfusion abnormalities to explain early COVID-19 hypoxemia. Nat Commun. 2020;11:4883.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  40. 40.

    Kory P, Kanne JP. SARS-CoV-2 organising pneumonia: ‘has there been a widespread failure to identify and treat this prevalent condition in COVID-19?’. BMJ Open Respir Res. 2020;7:e000724.

    PubMed  Article  PubMed Central  Google Scholar 

  41. 41.

    Tobin MJ, Laghi F, Jubran A. Why COVID-19 silent hypoxemia is baffling to physicians. Am J Respir Crit Care Med. 2020;202:356–60.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  42. 42.

    Brouqui P, Amrane S, Million M, Cortaredona S, Parola P, Lagier JC, et al. Asymptomatic hypoxia in COVID-19 is associated with poor outcome. Int J Infect Dis. 2020;102:233–8.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  43. 43.

    Jounieaux V, Rodenstein DO, Mahjoub Y. On happy hypoxia and on sadly ignored “acute vascular distress syndrome” in patients with COVID-19. Am J Respir Crit Care Med. 2020;202:1598–9.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  44. 44.

    Grieco DL, Bongiovanni F, Chen L, Menga LS, Cutuli SL, Pintaudi G, et al. Respiratory physiology of COVID-19-induced respiratory failure compared to ARDS of other etiologies. Crit Care. 2020;24:529.

    PubMed  PubMed Central  Article  Google Scholar 

  45. 45.

    Kim PS, Read SW, Fauci AS. Therapy for early COVID-19: a critical need. JAMA. 2020;324:2149–50.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  46. 46.

    Cai Y, Hao Z, Gao Y, Ping W, Wang Q, Peng S, et al. Coronavirus Disease 2019 in the perioperative period of lung resection: a brief report from a single thoracic surgery department in Wuhan, People’s Republic of China. J Thorac Oncol. 2020;15:1065–72.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  47. 47.

    Tian S, Hu W, Niu L, Liu H, Xu H, Xiao SY. Pulmonary pathology of early-phase 2019 novel coronavirus (COVID-19) pneumonia in two patients with lung cancer. J Thorac Oncol. 2020;15:700–4.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  48. 48.

    Pernazza A, Mancini M, Rullo E, Bassi M, De Giacomo T, Della, et al. Early histologic findings of pulmonary SARS-CoV-2 infection detected in a surgical specimen. Virchows Arch. 2020;477:743–8.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  49. 49.

    Zeng Z, Xu L, Xie XY, Yan-H, Xie B, Xu W, et al. Pulmonary pathology of early phase COVID-19 pneumonia in a patient with a benign lung lesion. Histopathology 2020;77:823–31.

    PubMed  Article  PubMed Central  Google Scholar 

  50. 50.

    Çınar HNU, İnce Ö, Çelik B, Saltabaş F, Özbek M. Clinical course of COVID-19 pneumonia in a patient undergoing pneumonectomy and pathology findings during the incubation period. Swiss Med Wkly. 2020;150:w20302.

    PubMed  PubMed Central  Google Scholar 

  51. 51.

    Joob B, Wiwanitkit V. Pulmonary pathology of early phase 2019 novel coronavirus pneumonia. J Thorac Oncol. 2020;15:e67.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  52. 52.

    Tian S, Xiao SY. Pathology of 2019 novel coronavirus pneumonia: a dynamic disease process. J Thorac Oncol. 2020;15:e67–8.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  53. 53.

    Doglioni C, Ravaglia C, Chilosi M, Rossi G, Dubini A, Pedica F, et al. Covid-19 interstitial pneumonia: histological and immunohistochemical features on cryobiopsies. Respiration. 2021;16:1–11.

  54. 54.

    Hou YJ, Okuda K, Edwards CE, Martinez DR, Asakura T, Dinnon KH, et al. SARS-CoV-2 Reverse genetics reveals a variable infection gradient in the respiratory tract. Cell. 2020;182:429–46.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  55. 55.

    Zhang H, Penninger JM, Li Y, Zhong N, Slutsky AS. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med. 2020;46:586–90.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  56. 56.

    Qi F, Qian S, Zhang S, Zhang Z. Single cell RNA sequencing of 13 human tissues identify cell types and receptors of human coronaviruses. Biochem Biophys Res Commun. 2020;526:135–40.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  57. 57.

    Hoffmann M, Kleine-Weber H, Schroeder S, Kruger N, Herrler T, Erichsen S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181:271.e8.

    Article  CAS  Google Scholar 

  58. 58.

    Massoth LR, Desai N, Szabolcs A, Harris CK, Neyaz A, Crotty R, et al. Comparison of RNA in situ hybridization and immunohistochemistry techniques for the detection and localization of SARS-CoV-2 in human tissues. Am J Surg Pathol. 2021;45:14–24.

    PubMed  Article  PubMed Central  Google Scholar 

  59. 59.

    Liu J, Babka AM, Kearney BJ, Radoshitzky SR, Kuhn JH, Zeng X. Molecular detection of SARS-CoV-2 in formalin-fixed, paraffin-embedded specimens. JCI Insight. 2020;5:e139042.

    PubMed Central  Article  Google Scholar 

  60. 60.

    Schaefer IM, Padera RF, Solomon IH, Kanjilal S, Hammer MM, Jason L, et al. In situ detection of SARS-CoV-2 in lungs and airways of patients with COVID-19. Mod Pathol. 2020;33:2104–14.

    CAS  PubMed  Article  Google Scholar 

  61. 61.

    Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R, Zinkernagel AS, et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020;395:1417–8.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  62. 62.

    Martines RB, Ritter JM, Matkovic E, Gary J, Bollweg BC, Bullock H, et al. COVID-19 Pathology Working Group. Pathology and pathogenesis of fatal COVID-19 cases associated with SARS-CoV-2 pandemic. Emerg Infect Dis. 2020;26:2005–15.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  63. 63.

    El-Zammar O, Rosenbaum P, Katzenstein AL. Proliferative activity in fibrosing lung diseases: a comparative study of Ki-67 immunoreactivity in diffuse alveolar damage, bronchiolitis obliterans-organizing pneumonia, and usual interstitial pneumonia. Hum Pathol. 2009;40:1182–8.

    CAS  PubMed  Article  Google Scholar 

  64. 64.

    Ware LB, Matthay MA. The acute respiratory distress syndrome. N Engl J Med. 2000;342:1334–9.

    CAS  PubMed  Article  Google Scholar 

  65. 65.

    Nabhan AN, Brownfield DG, Harbury PB, Krasnow MA, Desai TJ. Single-cell Wnt signaling niches maintain stemness of alveolar type 2 cells. Science. 2018;359:1118–23.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  66. 66.

    Chilosi M, Caliò A, Rossi A, Gilioli E, Pedica F, Montagna L, et al. Epithelial to mesenchymal transition-related proteins ZEB1, β-catenin, and β-tubulin-III in idiopathic pulmonary fibrosis. Mod Pathol. 2017;30:26–38.

    CAS  PubMed  Article  Google Scholar 

  67. 67.

    Hirano T. Interleukin 6 in inflammation, autoimmunity and cancer. Int Immunol. 2021;33:127–48.

    CAS  PubMed  Article  Google Scholar 

  68. 68.

    Brown RE, Wolf DA, Hunter RL, Zhao B, Buja LM. Morphoproteomics and etiopathogenic features of pulmonary COVID-19 with therapeutic implications: a case study. Ann Clin Lab Sci. 2020;50:308–13.

    CAS  PubMed  Google Scholar 

  69. 69.

    Matsuzaki Y, Besnard V, Clark JC, Xu Y, Wert SE, Ikegami M, et al. STAT3 regulates ABCA3 expression and influences lamellar body formation in alveolar type II cells. Am J Respir Cell Mol Biol. 2008;38:551–8.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  70. 70.

    Patra T, Meyer K, Geerling L, Isbell TS, Hoft DF, Brien J, et al. SARS-CoV-2 spike protein promotes IL-6 trans-signaling by activation of angiotensin II receptor signaling in epithelial cells. PLoS Pathog. 2020;16:e1009128.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  71. 71.

    Matsuyama T, Kubli SP, Yoshinaga SK, Pfeffer K, Mak TW. An aberrant STAT pathway is central to COVID-19. Cell Death Differ. 2020;27:3209–25.

    PubMed  Article  CAS  Google Scholar 

  72. 72.

    Murakami M, Kamimura D, Hirano T. Pleiotropy and specificity: insights from the interleukin 6 family of cytokines. Immunity. 2019;50:812–31.

    CAS  PubMed  Article  Google Scholar 

  73. 73.

    Hirano T, Murakami M. COVID-19: a new virus, but a familiar receptor and cytokine release syndrome. Immunity. 2020;52:731–3.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  74. 74.

    Xu X, Han M, Li T, Sun W, Wang D, Fu B, et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci USA. 2020;117:10970–5.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  75. 75.

    Bronte V, Ugel S, Tinazzi E, Vella A, De Sanctis F, Canè S, et al. Baricitinib restrains the immune dysregulation in patients with severe COVID-19. J Clin Investig. 2020;130:6409–16.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  76. 76.

    Nägele MP, Haubner B, Tanner FC, Ruschitzka F, Flammer AJ. Endothelial dysfunction in COVID-19: Current findings and therapeutic implications. Atherosclerosis. 2020;314:58–62.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  77. 77.

    O’Sullivan JM, Gonagle DM, Ward SE, Preston RJS, O’Donnell JS. Endothelial cells orchestrate COVID-19 coagulopathy. Lancet Haematol. 2020;7:e553–5.

    PubMed  PubMed Central  Article  Google Scholar 

  78. 78.

    Teuwen LA, Geldhof V, Pasut A, Carmeliet P. COVID-19: the vasculature unleashed. Nat Rev Immunol. 2020;20:389–91.

    CAS  Article  Google Scholar 

  79. 79.

    Mangalmurti NS, Reilly JP, Cines DB, Hunter CA, Meyer NJ, Vaughan AE. COVID-ARDS clarified: a vascular endotype? Am J Respir Crit Care Med. 2020;202:750–3.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  80. 80.

    Guan WJ, Liang WH, Zhao Y, Liang HR, Chen ZS, Li YM, et al. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. Eur Respir J. 2020;55:2000547.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  81. 81.

    Simonnet A, Chetboun M, Poissy J, Raverdy V, Noulette J, Duhamel A, et al. High prevalence of obesity in severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) requiring invasive mechanical ventilation. Obesity. 2020;28:1195–9.

    CAS  PubMed  Article  Google Scholar 

  82. 82.

    Ni W, Yang X, Yang D, Bao J, Li R, Xiao Y, et al. Role of angiotensin-converting enzyme 2 (ACE2) in COVID-19. Crit Care. 2020;24:422.

    PubMed  PubMed Central  Article  Google Scholar 

  83. 83.

    Bourgonje AR, Abdulle AE, Timens W, Hillebrands JL, Navis GJ, Gordijn SJ, et al. Angiotensin-converting enzyme 2 (ACE2), SARS-CoV-2 and the pathophysiology of coronavirus disease 2019 (COVID-19). J Pathol. 2020;251:228–48.

    CAS  Article  Google Scholar 

  84. 84.

    Goldsmith CS, Miller SE, Martines RB, Bullock HA, Zaki SR. Electron microscopy of SARS-CoV-2: a challenging task. Lancet. 2020;395:e99.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  85. 85.

    Miller SE. Visualization of SARS-CoV-2 in the lung. N Engl J Med. 2020;383:2689–90.

    CAS  PubMed  Article  Google Scholar 

  86. 86.

    Baeck M, Hoton D, Marot L, Herman A. Chilblains and COVID-19: why SARS-CoV-2 endothelial infection is questioned. Br J Dermatol. 2020;183:1152–3.

    CAS  PubMed  Article  Google Scholar 

  87. 87.

    Wazny V, Siau A, Wu KX, Cheung C. Vascular underpinning of COVID-19. Open Biol. 2020;10:200208.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  88. 88.

    Watanabe T, Barker TA, Berk BC. Angiotensin II and the endothelium: diverse signals and effects. Hypertension. 2005;45:163–9.

    CAS  PubMed  Article  Google Scholar 

  89. 89.

    Liu Y, Yang Y, Zhang C, Huang F, Wang F, Yuan J, et al. Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury. Sci China Life Sci. 2020;63:364–74.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  90. 90.

    Alsaffar H, Martino N, Garrett JP, Adam AP. Interleukin-6 promotes a sustained loss of endothelial barrier function via Janus kinase-mediated STAT3 phosphorylation and de novo protein synthesis. Am J Physiol Cell Physiol. 2018;314:C589–602.

    CAS  PubMed  Article  Google Scholar 

  91. 91.

    Rauch A, Dupont A, Goutay J, Caplan M, Staessens S, Moussa M, et al. Endotheliopathy is induced by plasma from critically Ill patients and associated with organ failure in severe COVID-19. Circulation. 2020;142:1881–4.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  92. 92.

    Suzuki YJ, Nikolaienko SI, Dibrova VA, Dibrova YV, Vasylyk VM, Novikov MY, et al. SARS-CoV-2 spike protein-mediated cell signaling in lung vascular cells. Vasc Pharmacol. 2020;137:106823.

    Article  CAS  Google Scholar 

  93. 93.

    Choudhury A, Mukherjee S. In silico studies on the comparative characterization of the interactions of SARS-CoV-2 spike glycoprotein with ACE-2 receptor homologs and human TLRs. J Med Virol. 2020;92:2105–13.

    CAS  PubMed  Article  Google Scholar 

  94. 94.

    Song G, Li L, Yang Y. MicroRNA-329-3p alleviates high glucose-induced endothelial cell injury via inhibition of the TLR4/TRAF6/NF-κB signaling pathway. Exp Ther Med. 2021;21:29.

    CAS  PubMed  Google Scholar 

  95. 95.

    Potus F, Mai V, Lebret M, Malenfant S, Breton-Gagnon E, Lajoie AC, et al. Novel insights on the pulmonary vascular consequences of COVID-19. Am J Physiol Lung Cell Mol Physiol. 2020;319:L277–88.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  96. 96.

    Guervilly C, Burtey S, Sabatier F, Cauchois R, Lano G, Abdili E, et al. Circulating endothelial cells as a marker of endothelial injury in severe COVID -19. J Infect Dis. 2020;222:1789–93.

    CAS  PubMed  Article  Google Scholar 

  97. 97.

    Chatterjee V, Yang X, Ma Y, Wu MH, Yuan SY. Extracellular vesicles: new players in regulating vascular barrier function. Am J Physiol Heart Circ Physiol. 2020;319:H1181–96.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  98. 98.

    Xu S, Pan X, Mao L, Pan H, Xu W, Hu Y, et al. Phospho-Tyr705 of STAT3 is a therapeutic target for sepsis through regulating inflammation and coagulation. Cell Commun Signal. 2020;18:104.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  99. 99.

    Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost. 2020;18:1094–9.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  100. 100.

    Zhang Q, Mu X, Dong H, Hu G, Zhang T, He C, et al. Pulmonary endothelium-derived PD-L1 induced by the H9N2 avian influenza virus inhibits the immune response of T cells. Virol J. 2020;17:92.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  101. 101.

    Eppihimer MJ, Gunn J, Freeman GJ, Greenfield EA, Chernova T, Erickson J, et al. Expression and regulation of the PD-L1 immunoinhibitory molecule on microvascular endothelial cells. Microcirculation. 2002;9:133–45.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  102. 102.

    Taguchi K, Onoe T, Yoshida T, Yamashita Y, Tanaka Y, Ohdan H. Tumor endothelial cell-mediated antigen-specific T-cell suppression via the PD-1/PD-L1 pathway. Mol Cancer Res. 2020;18:1427–40.

    CAS  PubMed  Article  Google Scholar 

  103. 103.

    Liu S, Qin T, Liu Z, Wang J, Jia Y, Feng Y, et al. anlotinib alters tumor immune microenvironment by downregulating PD-L1 expression on vascular endothelial cells. Cell Death Dis. 2020;11:309.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  104. 104.

    Monaghan SF, Thakkar RK, Heffernan DS, Huang X, Chung CS, Lomas-Neira J, et al. Mechanisms of indirect acute lung injury: a novel role for the coinhibitory receptor, programmed death-1. Ann Surg. 2012;255:158–64.

    PubMed  Article  Google Scholar 

  105. 105.

    Xu S, Yang Q, Bai J, Tao T, Tang L, Chen Y, et al. Blockade of endothelial, but not epithelial, cell expression of PD-L1 following severe shock attenuates the development of indirect acute lung injury in mice. Am J Physiol Lung Cell Mol Physiol. 2020;318:L801–12.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  106. 106.

    Lomas-Neira J, Monaghan SF, Huang X, Fallon EA, Chung CS, Ayala A. Novel role for PD-1:PD-L1 as mediator of pulmonary vascular endothelial cell functions in pathogenesis of indirect ARDS in mice. Front Immunol. 2018;9:3030.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  107. 107.

    Gazdhar A, Blank F, Cesson V, Lovis A, Aubert JD, Lazor R, et al. Human bronchial epithelial cells induce CD141/CD123/DC-SIGN/FLT3 monocytes that promote allogeneic Th17 differentiation. Front Immunol. 2017;8:447.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  108. 108.

    Roquilly A, Jacqueline C, Davieau M, Mollé A, Sadek A, Fourgeux C, et al. Alveolar macrophages are epigenetically altered after inflammation, leading to long-term lung immunoparalysis. Nat Immunol. 2020;21:636–48.

    CAS  PubMed  Article  Google Scholar 

  109. 109.

    Falck-Jones S, Vangeti S, Yu M, Falck-Jones R, Cagigi A, Badolati I, et al. Functional monocytic myeloid-derived suppressor cells increase in blood but not airways and predict COVID-19 severity. J Clin Investig. 2021;25:144734.

    Article  Google Scholar 

  110. 110.

    Merad M, Martin JC. Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages. Nat Rev Immunol. 2020;20:355–62.

    CAS  PubMed  Article  Google Scholar 

  111. 111.

    Chua RL, Lukassen S, Trump S, Hennig BP, Wendisch D, Pott F, et al. COVID-19 severity correlates with airway epithelium–immune cell interactions identified by single-cell analysis. Nat Biotechnol. 2020;38:970–9.

    CAS  PubMed  Article  Google Scholar 

  112. 112.

    Yeung AW, Terentis AC, King NJ, Thomas SR. Role of indoleamine 2,3-dioxygenase in health and disease. Clin Sci. 2015;129:601–72.

    CAS  Article  Google Scholar 

  113. 113.

    Mehraj V, Routy JP. Tryptophan catabolism in chronic viral infections: handling uninvited guests. Int J Tryptophan Res. 2015;8:41–8.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  114. 114.

    Beutelspacher SC, Tan PH, McClure MO, Larkin DF, Lechler RI, George AJ. Expression of indoleamine 2,3-dioxygenase (IDO) by endothelial cells: implications for the control of alloresponses. Am J Transplant. 2006;6:1320–30.

    CAS  PubMed  Article  Google Scholar 

  115. 115.

    Li Q, Harden JL, Anderson CD, Egilmez NK. Tolerogenic phenotype of IFN-γ-induced IDO+ dendritic cells is maintained via an autocrine IDO-kynurenine/AhR-IDO loop. J Immunol. 2016;197:962–70.

    CAS  PubMed  Article  Google Scholar 

  116. 116.

    Heidari F, Ramezani A, Erfani N, Razmkhah M. Indoleamine 2, 3-Dioxygenase: a professional immunomodulator and its potential functions in immune related diseases. Int Rev Immunol Oct. 2020;29:1–18.

    Google Scholar 

  117. 117.

    Zheng M, Gao Y, Wang G, Song G, Liu S, Sun D, et al. Functional exhaustion of antiviral lymphocytes in COVID-19 patients. Cell Mol Immunol. 2020;17:533–5.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  118. 118.

    Wu H, Gong J, Liu Y. Indoleamine 2, 3-dioxygenase regulation of immune response. Mol Med Rep. 2018;17:4867–73.

    CAS  PubMed  Google Scholar 

  119. 119.

    Zardoya-Laguardia P, Blaschitz A, Hirschmugl B, Lang I, Herzog SA, Nikitina L, et al. Endothelial indoleamine 2,3-dioxygenase-1 regulates the placental vascular tone and is deficient in intrauterine growth restriction and pre-eclampsia. Sci Rep. 2018;8:5488.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  120. 120.

    Smith C, Chang MY, Parker KH, Beury DW, DuHadaway JB, Flick HE, et al. IDO is a nodal pathogenic driver of lung cancer and metastasis development. Cancer Discov. 2012;2:722–35.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  121. 121.

    Wang Y, Liu H, McKenzie G, Witting PK, Stasch JP, Hahn M, et al. Kynurenine is an endothelium-derived relaxing factor produced during inflammation. Nat Med. 2010;16:279–85.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  122. 122.

    Hofmann F. Ido brings down the pressure in systemic inflammation. Nat Med. 2010;16:265–7.

    CAS  PubMed  Article  Google Scholar 

  123. 123.

    Lim YJ, Foo TC, Yeung AWS, Tu X, Ma Y, Hawkins CL, et al. Human indoleamine 2,3-dioxygenase 1 is an efficient mammalian nitrite reductase. Biochemistry. 2019;58:974–86.

    CAS  PubMed  Article  Google Scholar 

  124. 124.

    Förstermann U. Oxidative stress in vascular disease: causes, defense mechanisms and potential therapies. Nat Clin Pract Cardiovasc Med. 2008;5:338–49.

    PubMed  Article  CAS  Google Scholar 

  125. 125.

    Lv H, Chen T, Pan Y, Wang H, Chen L, Lu Y. Pulmonary vascular enlargement on thoracic CT for diagnosis and differential diagnosis of COVID-19: a systematic review and meta-analysis. Ann Transl Med. 2020;8:878.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  126. 126.

    Piciucchi S, Ravaglia C, Vizzuso A, Bertocco M, Poletti V. Reversibility of venous dilatation and parenchymal changes density in Sars-Cov-2 pneumonia: toward the definition of a peculiar pattern. Pulmonology. 2020;S2531-0437(20)30227-0. Epub ahead of print.

  127. 127.

    Marini JJ. Dealing With the CARDS of COVID-19. Crit Care Med. 2020;48:1239–41.

    CAS  PubMed  Article  Google Scholar 

  128. 128.

    Singh K, Kadnur H, Ray A, Khanna P, Singh A, Wig N, et al. Platypnea-orthodeoxia in a patient with severe COVID-19 pneumonia. Monaldi Arch Chest Dis Dec. 2020;23:90.

    Google Scholar 

  129. 129.

    Longo C, Ruffini L, Zanoni N, Longo F, Accogli R, Graziani T, et al. Platypnea-orthodeoxia after fibrotic evolution of SARS-CoV-2 interstitial pneumonia. A case report. Acta Biomed. 2020;10:91.

    Google Scholar 

  130. 130.

    Xiao Y, Christou H, Liu L, Visner G, Mitsialis SA, Kourembanas S, et al. Endothelial indoleamine 2,3-dioxygenase protects against development of pulmonary hypertension. Am J Respir Crit Care Med. 2013;188:482–91.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  131. 131.

    Lee SM, Park HY, Suh YS, Yoon EH, Kim J, Jang WH, et al. Inhibition of acute lethal pulmonary inflammation by the IDO-AhR pathway. Proc Natl Acad Sci USA. 2017;114:E5881–90.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  132. 132.

    Hoshi M, Matsumoto K, Ito H, Ohtaki H, Arioka Y, Osawa Y, et al. L-tryptophan-kynurenine pathway metabolites regulate type I IFNs of acute viral myocarditis in mice. J Immunol. 2012;188:3980–7.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  133. 133.

    Meffre E, Iwasaki A. Interferon deficiency can lead to severe COVID. Nature. 2020;587:374–6.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  134. 134.

    Hadjadj J, Yatim N, Barnabei L, Corneaua A, Boussier J, Smith N, et al. Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients. Science. 2020;369:718–24.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  135. 135.

    Zhang Q, Bastard P, Liu Z, Le Pen J, Moncada-Velez M, Chen J, et al. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science. 2020;370:eabd4570.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  136. 136.

    Wang Z, Pan H, Jiang B. Type I IFN deficiency: an immunological characteristic of severe COVID-19 patients. Signal Transduct Target Ther. 2020;5:198.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  137. 137.

    Stefan N, Birkenfeld AL, Schulze MB, Ludwig DS. Obesity and impaired metabolic health in patients with COVID-19. Nat Rev Endocrinol. 2020;16:341–2.

    CAS  Article  Google Scholar 

  138. 138.

    Brandacher G, Hoeller E, Fuchs D, Weiss HG. Chronic immune activation underlies morbid obesity: is IDO a key player? Curr Drug Metab. 2007;8:289–95.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  139. 139.

    Zamanakou M, Germenis AE, Karanikas V. Tumor immune escape mediated by indoleamine 2,3-dioxygenase. Immunol Lett. 2007;111:69–75.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  140. 140.

    Liang Y, Yu Z, Song Y, Wang T, Xiao B. Indoleamine 2,3-dioxygenase activation by interferon gamma in vascular endothelial rat cells requires noncanonical NF-κB signaling. Transpl Proc. 2019;51:2141–5.

    CAS  Article  Google Scholar 

  141. 141.

    Liu JB, Chen D, Bao TT, Fan FT, Yu C. The anticancer effects of atractylenolide iii associate with the downregulation of Jak3/Stat3-dependent IDO expression. Front Pharmacol. 2020;10:1505.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  142. 142.

    Barber DL, Wherry EJ, Masopust D, Zhu B, Allison JP, Sharpe AH, et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature. 2006;439:682–7.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  143. 143.

    Erickson JJ, Gilchuk P, Hastings AK, Tollefson SJ, Johnson M, Downing MB, et al. Viral acute lower respiratory infections impair CD8+ T cells through PD-1. J Clin Investig. 2012;122:2967–82.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  144. 144.

    Wang P, Luo R, Zhang M, Wang Y, Song T, Tao T, et al. A cross-talk between epithelium and endothelium mediates human alveolar-capillary injury during SARS-CoV-2 infection. Cell Death Dis. 2020;11:1042.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  145. 145.

    Li Q, Huang XT, Li CH, Liu D, Lv FJ. CT features of coronavirus disease 2019 (COVID-19) with an emphasis on the vascular enlargement pattern. Eur J Radiol. 2020;134:109442.

    PubMed  PubMed Central  Article  Google Scholar 

  146. 146.

    Gormeli Kurt N, Gunes C. Retrospective analysis of asymptomatic COVID-19 patients presenting to emergency department. Int J Clin Pract 2021;75:e13913.

    CAS  PubMed  Google Scholar 

  147. 147.

    Meng H, Xiong R, He R, Lin W, Hao B, Zhang L, et al. CT imaging and clinical course of asymptomatic cases with COVID-19 pneumonia at admission in Wuhan, China. J Infect. 2020;81:e33–9.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  148. 148.

    Dupont T, Caillat-Zucman S, Fremeaux-Bacchi V, Morin F, Lengliné E, Darmon M. Identification of distinct immunophenotypes in critically-ill COVID-19 patients. Chest. 2020;S0012-3692(20)35351-4.

  149. 149.

    Grant RA, Morales-Nebreda L, Markov NS, Swaminathan S, Querrey M, Guzman ER, et al. Circuits between infected macrophages and T cells in SARS-CoV-2 pneumonia. Nature. 2021;590:635–41.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  150. 150.

    Sanchez-Vazquez R, Guío-Carrión A, Zapatero-Gaviria A, Martínez P, Blasco MA. Shorter telomere lengths in patients with severe COVID-19 disease. Aging. 2021;13:1–15.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

Download references


We thank Fondazione Cariverona (ENACT Project) for the financial support.

Author information




MC, CD, and VP conceived and wrote the paper; CR, GR, AD, FP, SP, GP, GM, and VB contributed to data retrieval and interpretation; all authors took part in analyzing the data raising hypotheses, commented on drafts of the paper, and contributed to writing of the final version of the paper.

Corresponding author

Correspondence to Marco Chilosi.

Ethics declarations

Conflict of interest

The author declares no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Chilosi, M., Poletti, V., Ravaglia, C. et al. The pathogenic role of epithelial and endothelial cells in early-phase COVID-19 pneumonia: victims and partners in crime. Mod Pathol 34, 1444–1455 (2021).

Download citation


Quick links